SCHOTT Pharma (1SXP) Corporate presentation summary

At a glance / Investment case

• Provided over 12 billion drug containment solutions and delivery systems globally, serving all top 30 pharma companies.

• FY24 revenue reached €957 million with EBITDA of €258 million and a margin of 26.9%.

• High-value solutions (HVS) accounted for 55% of FY24 revenue, up 9 percentage points since FY20.

• Over 75% of new biologic drugs are delivered using these solutions.

• Average cash conversion exceeds 80%, supporting self-funded, profitable growth.

Who we are

• Global leader in drug containment and delivery, with a history of innovation since 1911.

• Every minute, more than 25,000 injections are delivered using their products.

• Revenue split: 62% drug containment, 38% drug delivery systems; 53% EMEA, 30% APAC, 17% Americas.

• Serves over 1,800 customers worldwide with a global production network.

• Operates in a highly regulated, consolidated market with significant barriers to entry and a strong IP-protected portfolio.

Strategy

• Positioned to benefit from healthcare megatrends like GLP-1, mRNA, ADCs, and homecare.

• Focus on expanding high-value solutions, which have a 12% CAGR and margins 10 percentage points above average.

• Ongoing capacity expansions in the US, Switzerland, Germany, Hungary, Serbia, and India.

• Maintains long-term, trusted relationships with customers, with 97% repeat business and a 90% customer satisfaction index.